Education
About Us
Working with TipRanks
Follow Us
Novavax (DE:NVV1)
FRANKFURT:NVV1
NVV1 Stock Chart & Stats
€8.18
-€1.01(-9.65%)
At close: 4:00 PM EST
€8.18
-€1.01(-9.65%)
Day’s Range― - ―
52-Week Range€4.82 - €8.57
Previous CloseN/A
Volume7.16K
Average Volume (3M)4.05K
Market Cap
€1.30B
Enterprise Value€1.53B
Total Cash (Recent Filing)€762.89M
Total Debt (Recent Filing)€251.14M
Price to Earnings (P/E)4.6
Beta2.73
Next Earnings
May 13, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.09
Shares Outstanding162,499,000
10 Day Avg. Volume2,106
30 Day Avg. Volume4,046
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)-1.96
Price to Sales (P/S)1.79
P/FCF Ratio-12.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.76Price Target Upside19.35% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)0.13
Revenue Forecast (FY)€394.29M
Bulls Say, Bears Say
Bulls Say
Adjuvant ValidationInterest from multiple pharmaceutical partners and a major licensing deal serve as external validation that Matrix-M could enhance vaccine performance across indications like RSV and pneumococcal disease.
Commercial TractionReported sales of Nuvaxovid and an updated financial model indicate early commercial traction that supported an analyst price-target increase and suggests market demand for the vaccine.
Licensing And RoyaltiesA non-exclusive license grants upfront payment, development and sales milestones, and tiered royalties for Matrix-M, creating a revenue stream while the partner handles commercialization.
Bears Say
Development Timing RiskMost financial upside depends on late-stage development and commercialization, but unclear timing of those milestones makes the arrival of milestone and royalty payments uncertain.
Market Demand And SentimentWeak scripts for COVID vaccines, pared-down market expectations, and ongoing negative headlines could suppress demand and weigh on investor sentiment for vaccine revenues.
Pipeline And Scientific RiskA limited number of Matrix-M collaboration programs nearing clinical trials and the higher scientific risk of bacterial vaccine efforts, such as a C. difficile vaccine, reduce near-term revenue visibility and increase development risk.
Novavax News
NVV1 FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was €4.82 and its highest was €8.57 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is €1.30B.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is May 13, 2026 which is in 76 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Feb 26, 2026. The company reported €0.093 earnings per share for the quarter, beating the consensus estimate of -€0.41 by €0.503.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -0.16.
How many shares outstanding does Novavax have?
Novavax has 162,499,000 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of €0.093 in its last earnings report, beating expectations of -€0.41. Following the earnings report the stock price went up 3.398%.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in DE:NVV1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novavax Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€9.76 (19.35% Upside)
€9.76 (19.35% Upside)
Blogger Sentiment
Bullish
DE:NVV1 Sentiment 75%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.91%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-31.10%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
NVV1 Company Deck
NVV1 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in strategic partnerships, cost reduction efforts, and financial improvements. However, there were notable challenges, including decreased product sales and a considerable net loss. The positive aspects slightly outweigh the negative, indicating a cautiously optimistic outlook.View all DE:NVV1 earnings summariesNVV1 Stock 12 Month Forecast
Average Price Target
€9.76
▲(19.35% Upside)
Technical Analysis
Vir Biotechnology
―
Oric Pharmaceuticals
―
CureVac
―
AbCellera Biologics
―
Sana Biotechnology
―
Options Prices
Currently, No data available
---